Stevens Capital Management LP Abb Vie Inc. Transaction History

Stevens Capital Management LP

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$132.51 - $164.9 $789,097 - $981,979	5,955 New	5,955 $802,000
Q4 2021 Jan 28, 2022	SELL	$107.43 - $135.93 $261,592 - $330,989	-2,435 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$106.4 - $120.78 $259,084 - $294,099	2,435 New	2,435 $263,000
Q4 2020 Feb 08, 2021	SELL	$80.49 - $108.67 $1.69 Million - $2.28 Million	-20,944 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$85.91 - $100.83 $1.03 Million - $1.21 Million	-11,996 Reduced 36.42%	20,944 $1.83 Million
Q2 2020 Aug 13, 2020	BUY	$73.37 - $98.18 $2.42 Million - $3.23 Million	32,940 New	32,940 $3.23 Million
Q1 2020 Apr 21, 2020	SELL	$64.5 - $97.79 $6.27 Million - $9.51 Million	-97,211 Closed	0 $0
Q4 2019 Feb 06, 2020	BUY	$72.13 - $90.25 $7.01 Million - $8.77 Million	97,211 New	97,211 $8.61 Million
Q3 2019 Nov 08, 2019	SELL	$62.98 - $75.72 $21.1 Million - $25.3 Million	-334,347 Closed	0 $0
Q2 2019 Jul 31, 2019	BUY	$65.7 - $83.98 $807,387 - $1.03 Million	12,289 Added 3.82%	334,347 $24.3 Million
Q1 2019 May 03, 2019	BUY	$77.14 - $90.79 $24.8 Million - $29.2 Million	322,058 New	322,058 $26 Million
Q4 2018 Feb 06, 2019	SELL	$77.85 - $96.01 $28.9 Million - $35.6 Million	-370,702 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$88.91 - $98.84 $2.34 Million - $2.61 Million	26,369 Added 7.66%	370,702 $35.1 Million
Q2 2018 Aug 09, 2018	BUY	$89.78 - $106.23 $17.4 Million - $20.6 Million	193,863 Added 128.84%	344,333 $31.9 Million
Q1 2018 May 08, 2018	BUY	$92.01 - $123.21 $13.8 Million - $18.5 Million	150,470 New	150,470 $14.2 Million

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Stevens Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Stevens Capital Management LP with notifications on news.